HOT COVID Trial
![](https://static.wixstatic.com/media/e4917c_55b8ae5f4b294b4da93e4a43d1b3df06~mv2.png/v1/fill/w_81,h_46,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/e4917c_55b8ae5f4b294b4da93e4a43d1b3df06~mv2.png)
In a multicenter trial involving 726 adults with COVID-19 and severe hypoxemia in European ICUs, targeting a partial pressure of oxygen (Pao2) of 60 mm Hg led to a median of 80 days alive without life support at 90 days, compared to 72 days for a Pao2 of 90 mm Hg (P=.009). No significant difference in mortality or serious adverse events was observed between the groups. This suggests that in severe COVID-19, a lower oxygenation target may improve outcomes without increasing risk.